Home Tags DLL3

Tag: DLL3

Phase II Study Evaluating Rovalpituzumab Tesirine Announced – AbbVie will Not...

After consulting with the U.S. Food and Drug Administration (FDA), AbbVie, a global research and development-based biopharmaceutical company, announced that the company will not...

Researchers Find SCLC-biopsy Specimen Reliable for Evaluating DLL3 Expression

High levels of delta-like protein 3 or DLL3 in small-cell lung cancer or SCLC are correlated with poor survival trends.  Li-Xu Yan, MD, a...

Rovalpituzumab Tesirine Shows Early Promise in Small Cell Lung Cancer

Rovalpituzumab tesirine (Rova-T or SC16LD6.5; AbbVie), a novel biomarker-specific 'smart-bomb' antibody-drug conjugate or ADC targeting the delta-like protein 3 or DLL3 protein, expressed in more...

X